Filing Flows › Cytosorbents (CTSO) › Q4 2025
Cytosorbents (CTSO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Cytosorbents (CTSO) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), +0.9% from a year earlier and -3% from the quarter before. Operating margin was -47.5%, net loss $5.5M (59.5% of revenue).
Cytosorbents, Q4 2025: revenue $9.2M (+0.9% year over year), operating margin -47.5%, net loss $5.5M, operating cash flow −$4.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | -3% | +0.9% |
| Operating profit | −$4.4M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$4.8M | — | — |
What changed
Revenue was $9.2M in Q4 2025, up 1% year over year and down 3% from the previous quarter.
Gross margin was 73.7%, up 5.3 points from Q4 2024. Operating costs exceeded revenue by $4.4M, an operating margin of -47.5%. Operating expenses grew 16% against revenue growth of 1%. The fastest-growing cost line was SG&A (+24%). The quarter ended with a net loss of $5.5M, wider than the previous quarter's $3.2M loss.
Operating cash flow was −$4.8M. Non-cash charges added back $97K of depreciation and amortization and $886K of share-based compensation. Working capital and other items used $311K. Capital expenditures of $108K exceeded it, leaving free cash flow of −$4.9M.
Questions
What was Cytosorbents' revenue in the fourth quarter 2025?
Cytosorbents (CTSO) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), +0.9% from a year earlier and -3% from the quarter before.
Was Cytosorbents profitable in the fourth quarter 2025?
Operating loss was $4.4M (-47.5% of revenue) and net loss $5.5M.
Source: Cytosorbents 10-K on SEC EDGAR.